GlassScriptPhysician profile
Jesse Tucker
NPI 1902148042
$4,567.84
in general payments reported to CMS, 2019-2025
25 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,602 · 2020: $262 · 2021: $29.02 · 2022: $190 · 2023: $305 · 2024: $867 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.65 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $2,371.43 | 2019 | |
| Glaxosmithkline, LLC. | $507.73 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $426.20 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Insmed, INC. | $203.25 | 2019-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.46 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Olympus America INC. | $114.58 | 2020 | |
| Electromed, INC. | $103.75 | 2023-2024 | Smartvest |
| Pfizer INC. | $102.35 | 2022-2025 | |
| Getinge USA Sales, LLC | $87.52 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $71.89 | 2022-2023 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $70.33 | 2023-2025 | Glassia |
| Grifols USA, LLC | $51.37 | 2024-2025 | Prolastin-C Liquid |
| Philips North America LLC | $49.69 | 2024 | (Ak6) Vest Therapy |
| United Therapeutics Corporation | $43.34 | 2022-2024 | Tyvaso |
| Fresenius USA Marketing, INC. | $37.21 | 2024 | Novalung System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $23.74 | 2023 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $23.42 | 2019 | |
| Genentech USA, INC. | $17.55 | 2020 | |
| Mallinckrodt Hospital Products INC. | $16.64 | 2022 | |
| Breas Medical, INC. | $14.40 | 2025 | Vivo 45 Ls |
| Viatris Specialty LLC | $14.20 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $14.00 | 2024 | Dupixent |
| Allergan, INC. | $12.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.10 | 2022 | |
| Haemonetics Corporation | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.